← Leaderboards
Jan Grimm
Sloan-Kettering Inst Can Research
$17,140,928
Attributed
$20,851,747
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,851,747 · 9
By mechanism
R01$20,134,989 · 8
R56$716,758 · 1
Top collaborators
- Brett Stewart Carver5 shared
- Vladimir Ponomarev3 shared
- Joaquin Lopez Herraiz2 shared
- Jose Manuel Udias Moinelo2 shared
- Zahi A. Fayad1 shared
- Carlos PãRez-Medina1 shared
- Thomas Reiner1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Michelle S Bradbury$7,087,200
- Brett Stewart Carver$12,016,524
- Joseph G Jurcic$858,939
- Jason S Lewis$26,024,327
- Thomas Reiner$4,804,085
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorMonitorImageSignal TransductionResponsePositron-Emission TomographyCancer TherapyBiologicalIn VivoBaseInnovationImaging ModalityCellsMagnetic Resonance ImagingCancer PatientCostNeoplastic CellCancer ImagingPenetrationSuccessMalignant Neoplasm Of ProstateNeoplasm MetastasisResistance
Grant awards (34)
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$734,548
R01 · FY2025 · CA · contact PI
Multicolor PET to interrogate cancer biology$673,118
R01 · FY2025 · EB · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$697,822
R01 · FY2024 · CA · contact PI
Multicolor PET to interrogate cancer biology$627,848
R01 · FY2024 · EB · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$719,857
R01 · FY2023 · CA · contact PI
Multicolor PET to interrogate cancer biology$659,909
R01 · FY2023 · EB · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$719,857
R01 · FY2022 · CA · contact PI
Cerenkov 2.0 â Cerenkov-activated agents for imaging and therapy$716,758
R56 · FY2022 · EB · contact PI
PSMAâs enzymatic activity as new target for Prostate Cancer diagnosis and therapy$734,548
R01 · FY2021 · CA · contact PI
Exploring PSMA Biology in Tumor neovasculature$731,830
R01 · FY2021 · CA · contact PI
PET nanoreporter image-guided breast cancer therapy$724,053
R01 · FY2021 · CA
Smart and self-reporting clinical nano carriers for drug delivery$691,044
R01 · FY2021 · CA · contact PI
Exploiting ferroportin for cancer imaging and therapy$521,740
R01 · FY2021 · CA · contact PI
Exploring PSMA Biology in Tumor neovasculature$731,830
R01 · FY2020 · CA · contact PI
Smart and self-reporting clinical nano carriers for drug delivery$702,224
R01 · FY2020 · CA · contact PI
Exploiting ferroportin for cancer imaging and therapy$521,740
R01 · FY2020 · CA · contact PI
Exploring PSMA Biology in Tumor neovasculature$709,876
R01 · FY2019 · CA · contact PI
Smart and self-reporting clinical nano carriers for drug delivery$689,833
R01 · FY2019 · CA · contact PI
Exploiting ferroportin for cancer imaging and therapy$506,089
R01 · FY2019 · CA · contact PI
Cerenkov luminescence imaging for image-guided cancer surgery$473,502
R01 · FY2019 · CA · contact PI
Exploring PSMA Biology in Tumor neovasculature$704,122
R01 · FY2018 · CA · contact PI
Smart and self-reporting clinical nano carriers for drug delivery$697,845
R01 · FY2018 · CA · contact PI
Exploiting ferroportin for cancer imaging and therapy$501,986
R01 · FY2018 · CA · contact PI
Cerenkov luminescence imaging for image-guided cancer surgery$488,147
R01 · FY2018 · CA · contact PI
Smart and self-reporting clinical nano carriers for drug delivery$713,953
R01 · FY2017 · CA · contact PI
Exploring PSMA Biology in Tumor neovasculature$631,933
R01 · FY2017 · CA · contact PI
Exploiting ferroportin for cancer imaging and therapy$604,800
R01 · FY2017 · CA · contact PI
Cerenkov luminescence imaging for image-guided cancer surgery$488,147
R01 · FY2017 · CA · contact PI
Cerenkov luminescence imaging for image-guided cancer surgery$511,313
R01 · FY2016 · CA · contact PI
Cerenkov luminescence imaging for image-guided cancer surgery$619,409
R01 · FY2015 · CA · contact PI
Cerenkov-emission based nanosensors to detect biologic activities in vivo$403,294
R01 · FY2015 · EB · contact PI
Cerenkov-emission based nanosensors to detect biologic activities in vivo$399,179
R01 · FY2014 · EB · contact PI
Cerenkov-emission based nanosensors to detect biologic activities in vivo$388,068
R01 · FY2013 · EB · contact PI
Cerenkov-emission based nanosensors to detect biologic activities in vivo$411,525
R01 · FY2012 · EB · contact PI